S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NYSE:NGMNGM Biopharmaceuticals Stock Price, Forecast & News

$18.51
-0.31 (-1.65 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.40
Now: $18.51
$19.00
50-Day Range
$17.91
MA: $19.32
$22.91
52-Week Range
$8.81
Now: $18.51
$23.95
Volume129,600 shs
Average Volume312,935 shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.6Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.97 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone650-243-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees186
Market Cap$1.26 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$18.51
-0.31 (-1.65 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NGM News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NGM Biopharmaceuticals (NYSE:NGM) Frequently Asked Questions

How has NGM Biopharmaceuticals' stock price been impacted by COVID-19?

NGM Biopharmaceuticals' stock was trading at $15.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NGM stock has increased by 20.6% and is now trading at $18.51.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of NGM Biopharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for NGM Biopharmaceuticals
.

When is NGM Biopharmaceuticals' next earnings date?

NGM Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for NGM Biopharmaceuticals
.

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals (NYSE:NGM) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.08.
View NGM Biopharmaceuticals' earnings history
.

What price target have analysts set for NGM?

8 brokerages have issued 1 year target prices for NGM Biopharmaceuticals' shares. Their forecasts range from $28.00 to $39.00. On average, they anticipate NGM Biopharmaceuticals' stock price to reach $31.38 in the next year. This suggests a possible upside of 69.5% from the stock's current price.
View analysts' price targets for NGM Biopharmaceuticals
.

What are Wall Street analysts saying about NGM Biopharmaceuticals stock?

Here are some recent quotes from research analysts about NGM Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California. " (7/22/2020)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $26 target price after NGM reported its 2Q19 financials and business update. We remain positively biased ahead of NGM282’s (aldafermin) Phase 2 cohort 4 interim data expected in 4Q19 (non-invasive biomarkers), but more importantly, aldafermin’s top line results in early 2020 where we believe it has the potential to demonstrate a histological fibrosis benefit in NASH patients in as little as 24 weeks of treatment. The latter remains the key catalyst for the stock, in our view. In the press release, NGM indicated it had completed enrollment for cohort 4 and management also highlighted pipeline progress for some of its earlier stage programs including for NGM621, which is being developed for geographic atrophy, and NGM120 for CACS." (8/14/2019)

Has NGM Biopharmaceuticals been receiving favorable news coverage?

Media headlines about NGM stock have trended extremely negative on Thursday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NGM Biopharmaceuticals earned a coverage optimism score of -4.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
View the latest news about NGM Biopharmaceuticals
.

Who are some of NGM Biopharmaceuticals' key competitors?

What other stocks do shareholders of NGM Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NGM Biopharmaceuticals investors own include Viking Therapeutics (VKTX), Alibaba Group (BABA), Opko Health (OPK), AbbVie (ABBV), Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX) and Fulcrum Therapeutics (FULC).

Who are NGM Biopharmaceuticals' key executives?

NGM Biopharmaceuticals' management team includes the following people:
  • Mr. William J. Rieflin J.D., Exec. Chairman of Directors (Age 60)
  • Dr. David J. Woodhouse, CEO, Acting CFO & Director (Age 49, Pay $615.75k)
  • Dr. Jin-Long Chen, Founder, Chief Scientific Officer & Director (Age 57, Pay $625.75k)
  • Dr. Aetna Wun Trombley, Consultant (Age 40, Pay $550.75k)
  • Ms. Valerie L. Pierce, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 57)

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGM."

Who are NGM Biopharmaceuticals' major shareholders?

NGM Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Svennilson Peter (25.99%), Candriam Luxembourg S.C.A. (0.34%), SG Americas Securities LLC (0.12%), Bank of New York Mellon Corp (0.12%), Goldman Sachs Group Inc. (0.09%) and RMB Capital Management LLC (0.08%). Company insiders that own NGM Biopharmaceuticals stock include David V Goeddel, Group L P Column, Hsiao D Lieu, Jin-Long Chen, Merck & Co, Inc, Peter Svennilson and Suzanne Sawochka Hooper.
View institutional ownership trends for NGM Biopharmaceuticals
.

Which institutional investors are selling NGM Biopharmaceuticals stock?

NGM stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Marshall Wace North America L.P., Bank of New York Mellon Corp, UBS Group AG, and Federated Hermes Inc.. Company insiders that have sold NGM Biopharmaceuticals company stock in the last year include Group L P Column, Hsiao D Lieu, and Jin-Long Chen.
View insider buying and selling activity for NGM Biopharmaceuticals
.

Which institutional investors are buying NGM Biopharmaceuticals stock?

NGM stock was purchased by a variety of institutional investors in the last quarter, including Svennilson Peter, SG Americas Securities LLC, RMB Capital Management LLC, Principal Financial Group Inc., California Public Employees Retirement System, Virtus ETF Advisers LLC, Raymond James Financial Services Advisors Inc., and Goldman Sachs Group Inc.. Company insiders that have bought NGM Biopharmaceuticals stock in the last two years include David V Goeddel, Group L P Column, Merck & Co, Inc, Peter Svennilson, and Suzanne Sawochka Hooper.
View insider buying and selling activity for NGM Biopharmaceuticals
.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $18.51.

How big of a company is NGM Biopharmaceuticals?

NGM Biopharmaceuticals has a market capitalization of $1.26 billion. NGM Biopharmaceuticals employs 186 workers across the globe.

What is NGM Biopharmaceuticals' official website?

The official website for NGM Biopharmaceuticals is www.ngmbio.com.

How can I contact NGM Biopharmaceuticals?

The company can be reached via phone at 650-243-5555.

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.